Seres Therapeutics, Inc.MCRBNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank77
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-1.88
↑ 67% vs avg
Percentile
P77
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-5.64
Historical baseline
PeriodValueYoY Change
2025-1.88-19.1%
2024-1.58-14.6%
2023-1.38+61.0%
2022-3.54+68.3%
2021-11.16+54.1%
2020-24.31-763.3%
2019-2.82-142.9%
2018-1.16+75.1%
2017-4.66-17.9%
2016-3.96-